David G. Matthews
Director of Finance/CFO at XORTX Pharma Corp.
Profile
David G.
Matthews is currently the Chief Financial Officer at XORTX Pharma Corp.
He previously worked as a Finance Director at Aspreva Pharmaceuticals Corp., Director at BMO Capital Partners, Director, Chief Financial & Accounting Officer at Many Bright Ideas Technologies, Inc., Managing Director at Aspreva Pharmaceuticals SA, Chief Financial Officer at Nventa Biopharmaceuticals Corp., Allelix Biopharmaceuticals, Inc., and Decipher Biosciences, Inc. Matthews holds an MBA degree from Clarkson University.
David G. Matthews active positions
| Companies | Position | Start |
|---|---|---|
XORTX Pharma Corp.
 XORTX Pharma Corp. Pharmaceuticals: MajorHealth Technology XORTX Pharma Corp. engages in the discovery, development, and commercialization of therapies for rare diseases. It develops cardio-vascular medications for the treatment of rare diseases such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, cystic fibrosis as well as large market diseases such as hypertension, metabolic syndrome, diabetes, and diabetic nephropathy. The company was founded in 2012 and is headquartered in Calgary, Canada. | Director of Finance/CFO | 28/02/2018 |
Former positions of David G. Matthews
| Companies | Position | End |
|---|---|---|
| XORTX THERAPEUTICS INC. | Director of Finance/CFO | 06/11/2018 |
BMO Capital Partners
 BMO Capital Partners Investment ManagersFinance BMO Capital Partners (BMO Capital) is a private equity subsidiary of BMO Equity Partners Inc. founded in 1996. The firm is headquartered in Toronto, Canada. | Director/Board Member | - |
Nventa Biopharmaceuticals Corp.
 Nventa Biopharmaceuticals Corp. Medical SpecialtiesHealth Technology Nventa Biopharmaceuticals Corp. discovered, developed and commercialized stress protein-based therapeutic vaccines. The company was headquartered in Victoria, Canada. | Director of Finance/CFO | - |
| Aspreva Pharmaceuticals SA | President | - |
Aspreva Pharmaceuticals Corp.
 Aspreva Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Aspreva Pharmaceuticals Corp. manufactured pharmaceutical products. It offered therapeutic products, research equipment, and related services. The firm developed drugs for the treatment of cancer, infectious diseases, and immune disorders. The company was founded in 2001 and is headquartered in Victoria, Canada. | Director of Finance/CFO | - |
Training of David G. Matthews
| Clarkson University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| MANY BRIGHT IDEAS TECHNOLOGIES INC. | Health Services |
| XORTX THERAPEUTICS INC. | Health Technology |
| Private companies | 7 |
|---|---|
Nventa Biopharmaceuticals Corp.
Nventa Biopharmaceuticals Corp. Medical SpecialtiesHealth Technology Nventa Biopharmaceuticals Corp. discovered, developed and commercialized stress protein-based therapeutic vaccines. The company was headquartered in Victoria, Canada. | Health Technology |
Aspreva Pharmaceuticals Corp.
Aspreva Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Aspreva Pharmaceuticals Corp. manufactured pharmaceutical products. It offered therapeutic products, research equipment, and related services. The firm developed drugs for the treatment of cancer, infectious diseases, and immune disorders. The company was founded in 2001 and is headquartered in Victoria, Canada. | Health Technology |
| Allelix Biopharmaceuticals, Inc. | Health Technology |
BMO Capital Partners
BMO Capital Partners Investment ManagersFinance BMO Capital Partners (BMO Capital) is a private equity subsidiary of BMO Equity Partners Inc. founded in 1996. The firm is headquartered in Toronto, Canada. | Finance |
Veracyte SD, Inc.
 Veracyte SD, Inc. Miscellaneous Commercial ServicesCommercial Services Decipher Biosciences, Inc. is a commercial-stage precision oncology company which engages in patient care improvement. The Company?s differentiated approach measures the biological activity of a patient?s entire tumor genome, known as whole transcriptome analysis, and applies proprietary machine learning algorithms to improve therapy selection and accelerate adoption of new therapies into the standard of care. Its novel prostate cancer genomic testing products examine the underlying biology of a patient?s tumor, enabling physicians to select an optimal therapy. The firm?s whole transcriptome analysis of clinical patient samples from its commercial channel and its participation in practice-changing clinical trials has allowed it to build and expand its Decipher GRID database GRID. The company was founded by Elai Davicioni, Timothy J. Triche, Bruce A. Schmidt, and Jonathan D. Buckley and is headquartered in San Diego, CA. | Commercial Services |
| Aspreva Pharmaceuticals SA | |
XORTX Pharma Corp.
XORTX Pharma Corp. Pharmaceuticals: MajorHealth Technology XORTX Pharma Corp. engages in the discovery, development, and commercialization of therapies for rare diseases. It develops cardio-vascular medications for the treatment of rare diseases such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, cystic fibrosis as well as large market diseases such as hypertension, metabolic syndrome, diabetes, and diabetic nephropathy. The company was founded in 2012 and is headquartered in Calgary, Canada. | Health Technology |
- Stock Market
- Insiders
- David G. Matthews
